Your session is about to expire
← Back to Search
Relatlimab + Nivolumab for Advanced Melanoma (RELATIVITY-047 Trial)
RELATIVITY-047 Trial Summary
This trial will compare the effectiveness of two drugs for treating melanoma that has spread or cannot be removed by surgery.
RELATIVITY-047 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRELATIVITY-047 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 & 2 trial • 578 Patients • NCT02488759RELATIVITY-047 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My melanoma is at an advanced stage and cannot be surgically removed.I have not received systemic anticancer therapy for my advanced melanoma.I can provide a tissue sample from my cancer that cannot be surgically removed.I do not have cancer that has spread to my brain or its coverings.I do not have eye melanoma.I do not have any known autoimmune diseases.
- Group 1: Arm A: Relatlimab + Nivolumab
- Group 2: Arm B: Nivolumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are people being recruited for this study right now?
"Currently, this clinical trial is not looking for more participants. However, this may change in the future as the study was last updated on September 8th, 2022. Additionally, there are 1530 other trials that are presently accepting patients."
What are the origins of this clinical trial?
"Relatlimab has been under investigation for a decade. In 2010, Medarex ran the first clinical trial with 127 participants. Based on the success of this study, Relatlimab received Phase 1 drug approval. At present, there are 749 active trials in 2348 cities and 50 countries."
How many individuals are enrolled in this clinical trial?
"Recruitment for this trial has ceased. The listing was first published on April 11th, 2018 and underwent its final edit on September 8th, 2022. There are 781 and 749 studies currently recruiting patients with melanoma and Relatlimab respectively."
What is Relatlimab's primary therapeutic purpose?
"Relatlimab is an immunotherapy medication that can be used to treat a patient suffering from malignant neoplasms, unresectable melanoma, or squamous cell carcinoma."
Are there any other drugs in development that are similar to Relatlimab?
"Relatlimab was first studied a decade ago, at H. Lee Moffitt Cancer Center and Research Institute. So far, there is a body of 249 completed studies to draw data from. Additionally, there are 749 active clinical trials involving relatlimab with many of these being performed in Montreal, Quebec."
In how many different medical settings is this research project being conducted today?
"Patients are currently being accepted at 50 different institutions across North America, including Local Institution - 0075 in Montreal, Quebec, Local Institution - 0120 in Baltimore, Maryland and Local Institution - 0018 in Charlotte, North carolina."
Share this study with friends
Copy Link
Messenger